A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Study summary

This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedGocatamig and Atezolizumab

Plus 1 other study approaches.

Who it may be forSmall-Cell Lung Cancer · Neuroendocrine Carcinoma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 24, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?11 U.S. locations

Locations may change over time.

Who runs it?Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Interventions being studied: Biological: Gocatamig; Biological: Atezolizumab; Biological: Ifinatamab Deruxtecan (I-DXd)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

The main inclusion criteria include but are not limited to the following:
Has a histologically or cytologically confirmed malignancy associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3)
Has small cell lung cancer (SCLC) which is relapsed/refractory following at least 1 prior line of systemic therapy that included platinum-based chemotherapy
Has Neuroendocrine Prostate Cancer (NEPC; de novo or treatment-emergent) which is relapsed/refractory to standard systemic therapy
Has high-grade neuroendocrine tumor types other than SCLC and NEPC, with at least one of the following:
Disease that is relapsed/refractory to standard systemic therapy
Disease for which standard therapy does not exist
Disease for which standard therapy is not considered appropriate by the Investigator
Must be able to provide archival tissue sample or fresh biopsy tissue sample

Reasons someone may not be able to joinExclusion criteria

The main

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer InstituteLos Angeles, California
University of California San FranciscoSan Francisco, California
University of ColoradoAurora, Colorado
Dana Farber Cancer InstituteBoston, Massachusetts
Karmanos Cancer CenterDetroit, Michigan
Roswell Park Comprehensive Cancer CenterBuffalo, New York
Memorial Sloan Kettering Cancer CenterNew York, New York
University Hospitals Cleveland Medical CenterCleveland, Ohio
ProvidencePortland, Oregon
Tennessee OncologyNashville, Tennessee
Medical College of WisconsinMilwaukee, Wisconsin

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 24, 2026. Always confirm current availability with the study team.

View original record ↗